Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279825 · ClinicalTrials.gov registry record · Phase 2
Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease
A Phase 2 study, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00279825 is a Phase 2 study that has completed, run by Impax Laboratories. The registered enrollment target is 16 participants.
The verdict
NCT00279825, a Phase 2 study, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The objective of this study is to compare the pharmacokinetics and pharmacodynamics of IPX054, carbidopa-levodopa immediate-release tablets, and carbidopa-levodopa controlled-release tablets in subjects with idiopathic Parkinson's disease.
Interventions
- DRUG IPX054 200 mg
- DRUG CD-LD IR
- DRUG IPX054 250 mg
- DRUG CD-LD CR
- DRUG IPX054 200 mg Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00279825
The ClinicalTrials.gov registry entry for NCT00279825 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Impax Laboratories, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which IPX054 200 mg is the first listed.
NCT00279825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00279825 about?
NCT00279825 is a clinical study titled "Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's Disease". The objective of this study is to compare the pharmacokinetics and pharmacodynamics of IPX054, carbidopa-levodopa immediate-release tablets, and carbidopa-levodopa controlled-release tablets in subjects with idiopathic Parkinson's disease.
What is the current status of trial NCT00279825?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2006-01. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00279825?
The interventions under investigation include: IPX054 200 mg (DRUG), CD-LD IR (DRUG), IPX054 250 mg (DRUG), CD-LD CR (DRUG), IPX054 200 mg Placebo (DRUG).
Who is sponsoring clinical trial NCT00279825?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.